Emerging role of lisocabtagene maraleucel chimeric antigen receptor-T cell in nodal and gastrointestinal follicular lymphoma

Table 1 Chimeric antigen receptor-T cell therapy clinical trials in relapsed/refractory follicular lymphoma

Ref.	Product	Target	Patients (n)	ORR/CR (%)	PFS/OS	Main AEs
Morschhauser et al[30]	Liso-cel	CD19	94 (FL)	97/73	NR/NR (30-month DOR 80%)	Neutropenia, anemia, low CRS/ICANS
Fowler et al[28]	Tisa-cel	CD19	97 (FL)	86/69	12-month PFS 67%; 12-month OS 92%	Neutropenia, ICANS (grade ≥ 3: 4%)
Jacobson et al[14]	Axi-cel	CD19	146 (FL)	94/79	17-month PFS 65%; 17-month OS 88%	CRS (any: 82%, ≥ 3: 7%), ICANS (≥ 3: 19%)
Shadman et al[21]	MB-106	CD20	28 (FL)	96/75	NR	Low CRS; no ICANS

FL: Follicular lymphoma; ORR: Overall response rate; CR: Complete response; PFS: Progression-free survival; OS: Overall survival; AE: Adverse event; CD: Cluster of differentiation; Liso-cel: Lisocabtagene maraleucel; Tisa-cel: Tisagenlecleucel; Axi-cel: Axicabtagene ciloleucel; NR: Not reached; DOR: Duration of response; CRS: Cytokine release syndrome; ICANS: Immune effector cell-associated neurotoxicity syndrome.